Peptide Safety Guide

Most peptides discussed on this site fall into one of four categories:

— FDA-approved drugs (Semaglutide, PT-141, Tesamorelin): Available by prescription. Manufactured under strict GMP conditions. Well-characterized safety profiles from clinical trials.

— Approved in other countries (Semax, Selank, Thymosin Alpha-1): Prescription drugs in Russia, Asia, or Europe. Not FDA-approved in the US but have clinical use histories.

— Clinical trial compounds (SS-31, Larazotide, Kisspeptin): In active clinical development. Some safety data from trials but not approved anywhere.

— Research compounds (BPC-157, TB-500, Epitalon, most GHRPs): Not approved for human use in any country. Sold as "research chemicals." No regulatory oversight on manufacturing quality.

For non-prescription peptides, quality varies enormously between suppliers. The primary risks are:

— Underdosed or overdosed product (you receive less or more than the label states) — Contamination (bacterial endotoxins, heavy metals, residual solvents from synthesis) — Incorrect peptide (wrong sequence, truncated peptide, or degraded product) — Lack of sterility (particularly dangerous for injectable products)

Minimum quality indicators to look for: — Third-party Certificate of Analysis (CoA) from an independent lab — HPLC purity testing (>98% purity for injectable peptides) — Endotoxin testing (LAL test) — Mass spectrometry confirmation of molecular identity

If a supplier cannot provide these, do not use their products.

Peptide use should ideally occur under the guidance of a healthcare provider who understands peptide pharmacology. This is especially important for:

— Peptides that affect hormonal systems (GH secretagogues, kisspeptin, semaglutide) — Peptides with known drug interactions — Individuals with pre-existing conditions (cancer history, diabetes, autoimmune disease) — Long-term protocols (>8 weeks)

Baseline and follow-up blood work is recommended for any protocol involving GH secretagogues (monitor IGF-1, fasting glucose, HbA1c), metabolic peptides (fasting glucose, lipids), or immune-modulating peptides (CBC, inflammatory markers).

The following contraindications apply to most peptides:

— Active cancer or history of cancer: Many peptides promote cell growth, angiogenesis, or inhibit apoptosis. These mechanisms could theoretically support tumor growth. This applies to BPC-157, TB-500, GH secretagogues, Epitalon, and any peptide that stimulates growth factors.

— Pregnancy and breastfeeding: Insufficient safety data exists for almost all non-approved peptides during pregnancy. Do not use.

— Known allergy to the specific peptide or any formulation component.

— Children/adolescents: Growth and development could be disrupted. Not studied in pediatric populations.

Discontinue use and consult a healthcare provider if you experience:

— Persistent pain, swelling, or redness at injection sites (possible infection) — Unexplained swelling in extremities that worsens (severe water retention) — Vision changes (could indicate diabetic retinopathy progression with GH peptides, or maculopathy with PPS) — Severe or persistent headaches — Heart palpitations or chest pain — Signs of allergic reaction (hives, difficulty breathing, facial swelling) — Any symptom that is unusual, persistent, or worsening

Do not "push through" adverse effects. The cost of stopping a cycle is near zero. The cost of ignoring a serious adverse reaction can be significant.

Infections from peptide injections are preventable with basic hygiene:

— Always use a new, sterile syringe for each injection — Swab vial tops and injection sites with alcohol before each use — Never touch the needle with your fingers — Never share vials or syringes — Dispose of used syringes in a sharps container — If an injection site becomes red, warm, swollen, or develops discharge, see a doctor immediately — these are signs of infection